email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
286 - 300
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
HutchMed’s Syk Inhibitor Meets Phase III Endpoints for Immune Thrombocytopenia
$5.00
Available
Innovent Approved to Launch PCSK9 Inhibitor in China for High-Cholesterol
$5.00
Available
CARsgen and Moderna to Test Dual Claudin18.2 Cancer Therapy Combo
$5.00
Available
Sangon Raises $290 Million for Life Science Tools and Services Business
$5.00
Available
Akeso Starts Phase III Trial of PD-1/VEGF Bispecific for NSCLC
$5.00
Available
CytoMed Signs MOU with CNK Therapeutics for Gene Grafting Technology in CAR Therapies
$5.00
Available
China Announces Plans to Facilitate Foreign Investments in its Biopharma Industry
$5.00
Available
OnCusp to Start US Trials of CDH6 ADC In-licensed from China’s Multitude
$5.00
Available
Zhongmei Huadong In-licenses Skin Disease Therapy in $94 Million Agreement
$5.00
Available
Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial
$5.00
Available
Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor
$5.00
Available
Neurophth Closes $95 Million Series C+ Round for Gene Therapy Ophthalmology Therapies
$5.00
Available
Jacobio Awarded China Breakthrough Status for KRAS Inhibitor in Pancreatic Cancer
$5.00
Available
AceLink Starts China Phase II Trial of Novel GCS Inhibitor for Fabry Disease
$5.00
Available
CanSinoBIO and AstraZeneca Form mRNA Vaccine Collaboration
$5.00
Available